Cardiff Oncology, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a stark dichotomy between clinical promise and financial peril. On one hand, the FDA's alignment on the Phase 3 trial design for onvansertib provides a concrete catalyst and validates the drug's potential as a breakthrough in mCRC. On the other hand, the explicit 'going concern' qualification and the legal battle with Nerviano introduce systemic risks that could derail the entire project regardless of clinical success. Investors are now faced with a high-stakes trade-off: the ability to capture the upside of a potential oncology blockbuster versus the risk of total loss due to insolvency or license termination. The immediate focus shifts to the upcoming ASCO presentation and any updates regarding the Nerviano dispute, as these will determine if the company can secure the funding necessary to execute its Phase 3 roadmap without destroying existing shareholder value.